The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: New therapeutic targets

Oncotarget

Volumn 6, Issue 34, 2015, Pages 35522-35541

  Liu, Wensheng ^b   Kovacevic, Zaklina ^a   Peng, Zhihai ^b   Jin, Runsen ^c   Wang, Puxiongzhi ^c   Yue, Fei ^c   Zheng, Minhua ^c   Huang, Michael L H ^a   Jansson, Patric J ^a   Richardson, Vera ^a   Kalinowski, Danuta S ^a   Lane, Darius J R ^a   Merlot, Angelica M ^a   Sahni, Sumit ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Metastasis; Metastasis suppressor; NDRG1; Src

Indexed keywords

ATRASENTAN; CD82 ANTIGEN; DI 2 PYRIDYLKETONE 4 CYCLOHEXYL 4 METHYL 3 THIOSEMICARBAZONE; DI 2 PYRIDYLKETONE 4,4, DIMETHYL 3 THIOSEMICARBAZONE; ETOPOSIDE; GENISTEIN; N MYC DOWNSTREAM REGULATED GENE 1; PROTEIN TYROSINE KINASE; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR 1; SRC SUPPRESSED C KINASE SUBSTRATE; THIOSEMICARBAZONE DERIVATIVE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CELL; CARCINOGENESIS; CD68 GENE; CELL MIGRATION; DRUG STRUCTURE; E CADHERIN GENE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INTRACELLULAR SIGNALING; METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOLECULARLY TARGETED THERAPY; NDRG1 GENE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RHOGDI2 GENE; SSECKS GENE; TUMOR SUPPRESSOR GENE; GENETICS; METABOLISM; NEOPLASMS; ONCOGENE SRC; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CARCINOGENESIS; GENES, SRC; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84946866405     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5849     Document Type: Article

References (184)

1. Hanahan D and Weinberg Robert A. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
2. Brugge JS and Erikson RL. Identification of a transformation-specific antigen induced by an avian sarcoma virus. Nature. 1977; 269:346-348.
3. Frame MC, Fincham VJ, Carragher NO and Wyke JA. v-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol. 2002; 3:233-245.
4. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol. 2001; 2:467-475.
5. Reynolds AB, Kanner SB, Bouton AH, Schaller MD, Weed SA, Flynn DC and Parsons JT. SRChing for the substrates of Src. Oncogene. 2014; 33:4537-4547.
6. Abram CL and Courtneidge SA. Src family tyrosine kinases and growth factor signaling. Exp Cell Res. 2000; 254:1-13.
7. Bromann PA, Korkaya H and Courtneidge SA. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004; 23:7957-7968.
8. Amanchy R, Zhong J, Hong R, Kim JH, Gucek M, Cole RN, Molina H and Pandey A. Identification of c-Src tyrosine kinase substrates in platelet-derived growth factor receptor signaling. Mol Oncol. 2009; 3:439-450.
9. Guarino M. Src signaling in cancer invasion. J Cell Physiol. 2010; 223:14-26.
10. Hynes NE and MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009; 21:177-184.
11. Chen PH, Chen X and He X. Platelet-derived growth factors and their receptors: structural and functional perspectives. Biochim Biophys Acta. 2013; 1834:2176-2186.
12. Desgrosellier JS and Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010; 10:9-22.
13. Talamonti MS, Roh MS, Curley SA and Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest. 1993; 91:53-60.
14. Nagathihalli NS and Merchant NB. Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. Front Biosci. 2012; 17:2059-2069.
15. Chang YM, Bai L, Liu S, Yang JC, Kung HJ and Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene. 2008; 27:6365-6375.
16. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer. 2004; 4:470-480.
17. Yan J, Yang Q and Huang Q. Metastasis suppressor genes. Histology Histopathol. 2013; 28:285-292.
18. Buchanan C, Lago Huvelle MA and Peters MG. Metastasis suppressors: basic and translational advances. Curr Pharm Biotechnology. 2011; 12:1948-1960.
19. Smith SC and Theodorescu D. Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer. 2009; 9:253-264.
20. Hurst DR and Welch DR. Metastasis suppressor genes at the interface between the environment and tumor cell growth. Int Rev Cell Mol Biol. 2011; 286:107-180.
21. Kurdistani SK, Arizti P, Reimer CL, Sugrue MM, Aaronson SA and Lee SW. Inhibition of tumor cell growth by RTP/rit42 and its responsiveness to p53 and DNA damage. Cancer Res. 1998; 58:4439-4444.
22. Kovacevic Z and Richardson DR. The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis. 2006; 27:2355-2366.
23. Sun J, Zhang D, Bae DH, Sahni S, Jansson P, Zheng Y, Zhao Q, Yue F, Zheng M, Kovacevic Z and Richardson DR. Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors. Carcinogenesis. 2013; 34:1943-1954.
24. Fang BA, Kovacevic Z, Park KC, Kalinowski DS, Jansson PJ, Lane DJ, Sahni S and Richardson DR. Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy. Biochim Biophys Acta. 2014; 1845:1-19.
25. Liu W, Xing F, Iiizumi-Gairani M, Okuda H, Watabe M, Pai SK, Pandey PR, Hirota S, Kobayashi A, Mo Y-Y, Fukuda K, et al. N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med. 2012; 4:93-108.
26. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, Saito K, Commes T, Hayashi S, Watabe M and Watabe K. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 2003; 63:1731-1736.
27. Maruyama Y. Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Res. 2006; 66:6233-6242.
28. Bandyopadhyay S, Pai SK, Hirota S, Hosobe S, Takano Y, Saito K, Piquemal D, Commes T, Watabe M, Gross SC, Wang Y, et al. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene. 2004; 23:5675-5681.
29. Kovacevic Z, Chikhani S, Lui GYL, Sivagurunathan S and Richardson DR. The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN, and SMAD4 and inhibits the PI3K and Ras signaling pathways. Antioxid Redox Signal. 2013; 18:874-887.
30. Liu W, Iiizumi-Gairani M, Okuda H, Kobayashi A, Watabe M, Pai SK, Pandey PR, Xing F, Fukuda K, Modur V, Hirota S, et al. KAI1 gene is engaged in NDRG1 gene-mediated metastasis suppression through the ATF3-NF B complex in human prostate cancer. J Biol Chem. 2011; 286:18949-18959.
31. Bandyopadhyay S, Pai SK, Hirota S, Hosobe S, Tsukada T, Miura K, Takano Y, Saito K, Commes T, Piquemal D, Watabe M, et al. PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer. Cancer Res. 2004; 64:7655-7660.
32. Dixon KM, Lui GY, Kovacevic Z, Zhang D, Yao M, Chen Z, Dong Q, Assinder SJ and Richardson DR. Dp44mT targets the AKT, TGF-beta and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. Br J Cancer. 2013; 108:409-419.
33. Chen Z, Zhang D, Yue F, Zheng M, Kovacevic Z and Richardson DR. The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem. 2012; 287:17016-17028.
34. Jin R, Liu W, Menezes S, Yue F, Zheng M, Kovacevic Z and Richardson DR. The metastasis suppressor NDRG1 modulates the phosphorylation and nuclear translocation of beta-catenin through mechanisms involving FRAT1 and PAK4. J Cell Sci. 2014; 127:3116-3130.
35. Sun J, Zhang D, Zheng Y, Zhao Q, Zheng M, Kovacevic Z and Richardson DR. Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway. Mol Pharmacol. 2012; 83:454-469.
36. Boggon TJ and Eck MJ. Structure and regulation of Src family kinases. Oncogene. 2004; 23:7918-7927.
37. Wheeler DL, Iida M and Dunn EF. The role of Src in solid tumors. Oncologist. 2009; 14:667-678.
38. Roskoski R, Jr. Src kinase regulation by phosphorylation and dephosphorylation. Biochem Biophys Res Commun. 2005; 331:1-14.
39. Okada M. Regulation of the SRC family kinases by Csk. Int J Biol Sci. 2012; 8:1385-1397.
40. Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta. 2008; 1784:56-65.
41. Huveneers DE. Adhesion signaling-crosstalk between integrins, Src and Rho. J Cell Sci. 2009; 122:1059-1069.
42. Avizienyte E and Frame MC. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol. 2005; 17:542-547.
43. Playford MP and Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene. 2004; 23:7928-7946.
44. Arpaia E, Blaser H, Quintela-Fandino M, Duncan G, Leong HS, Ablack A, Nambiar SC, Lind EF, Silvester J, Fleming CK, Rufini A, et al. The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene. 2012; 31:884-896.
45. Mader CC, Oser M, Magalhaes MA, Bravo-Cordero JJ, Condeelis J, Koleske AJ and Gil-Henn H. An EGFR-SrcArg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res. 2011; 71:1730-1741.
46. Cao H, Courchesne WE and Mastick CC. A phosphotyrosine-dependent protein interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14: recruitment of C-terminal Src kinase. J Biol Chem. 2002; 277:8771-8774.
47. Sato K, Nagao T, Kakumoto M, Kimoto M, Otsuki T, Iwasaki T, Tokmakov AA, Owada K and Fukami Y. Adaptor protein Shc is an isoform-specific direct activator of the tyrosine kinase c-Src. J Biol Chem. 2002; 277:29568-29576.
48. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA and Mills GB. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem. 2003; 278:40057-40066.
49. Hakak Y and Martin GS. Ubiquitin-dependent degradation of active Src. Curr Biol. 1999; 9:1039-1042.
50. Roskoski R, Jr. Src protein-tyrosine kinase structure and regulation. Biochem Biophys Res Comm. 2004; 324:1155-1164.
51. Piwnica-Worms H, Saunders KB, Roberts TM, Smith AE and Cheng SH. Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src. Cell. 1987; 49:75-82.
52. Friedl P and Alexander S. Cancer Invasion and the Microenvironment: Plasticity and Reciprocity. Cell. 2011; 147:992-1009.
53. Ishizawar R and Parsons SJ. c-Src and cooperating partners in human cancer. Cancer Cell. 2004; 6:209-214.
54. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA and Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. 2002; 94:344-351.
55. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY and Jove R. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005; 65:9185-9189.
56. Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C and Gambacorti-Passerini C. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(cSrc)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006; 66:2279-2286.
57. Chen J, Elfiky A, Han M, Chen C and Saif MW. The role of Src in colon cancer and its therapeutic Implications. Clin Colorectal Cancer. 2014; 13:5-13.
58. Ashour AA, Gurbuz N, Alpay SN, Abdel-Aziz AA, Mansour AM, Huo L and Ozpolat B. Elongation factor-2 kinase regulates TG2/beta1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion. J Cell Mol Med. 2014; 18:2235-2251.
59. Kanner SB, Reynolds AB, Wang HC, Vines RR and Parsons JT. The SH2 and SH3 domains of pp60src direct stable association with tyrosine phosphorylated proteins p130 and p110. EMBO J. 1991; 10:1689-1698.
60. Feng Q, Baird D, Peng X, Wang J, Ly T, Guan JL and Cerione RA. Cool-1 functions as an essential regulatory node for EGF receptor-and Src-mediated cell growth. Nat Cell Biology. 2006; 8:945-956.
61. Kelber JA, Reno T, Kaushal S, Metildi C, Wright T, Stoletov K, Weems JM, Park FD, Mose E, Wang Y, Hoffman RM, et al. KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. Cancer Res. 2012; 72:2554-2564.
62. Parsons SJ and Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene. 2004; 23:7906-7909.
63. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV and Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res. 2009; 15:6852-6861.
64. Malik FA, Sanders AJ and Jiang WG. KAI-1/CD82, the molecule and clinical implication in cancer and cancer metastasis. Histol Histopathol. 2009; 24:519-530.
65. Ichikawa T, Ichikawa Y and Isaacs JT. Genetic factors and suppression of metastatic ability of prostatic cancer. Cancer Res. 1991; 51:3788-3792.
66. Tsai YC and Weissman AM. Dissecting the diverse functions of the metastasis suppressor CD82/KAI1. FEBS Lett. 2011; 585:3166-3173.
67. Rathinam R and Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev. 2010; 29:223-237.
68. Sridhar SC and Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene. 2006; 25:2367-2378.
69. Odintsova E, Voortman J, Gilbert E and Berditchevski F. Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR. J Cell Sci. 2003; 116:4557-4566.
70. Odintsova E, Sugiura T and Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol. 2000; 10:1009-1012.
71. Birchmeier W, Brinkmann V, Niemann C, Meiners S, DiCesare S, Naundorf H and Sachs M. Role of HGF/SF and c-Met in morphogenesis and metastasis of epithelial cells. Ciba Foundation symposium. 1997; 212:230-240; discussion 240-236.
72. Park JJ, Jin YB, Lee YJ, Lee JS, Lee YS, Ko YG and Lee M. KAI1 suppresses HIF-1alpha and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer. BMC Cancer. 2012; 12:81.
73. Jee B, Jin K, Hahn J-H, Song H-G and Lee H. Metastasissuppressor KAI1-CD82 induces homotypic aggregation of human prostate cancer cells through Src-dependent pathway. Exp Mol Med. 2003; 35:30-37.
74. Ridley AJ. Cell migration: integrating signals from front to back. Science. 2003; 302:1704-1709.
75. Sanz-Moreno V and Marshall CJ. The plasticity of cytoskeletal dynamics underlying neoplastic cell migration. Curr Opin Cell Biol. 2010; 22:690-696.
76. Defilippi P, Di Stefano P and Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol. 2006; 16:257-263.
77. Gomez del Pulgar T, Benitah SA, Valeron PF, Espina C and Lacal JC. Rho GTPase expression in tumourigenesis: evidence for a significant link. Bioessays. 2005; 27:602-613.
78. Szczepanowska. J. Involvement of Rac-Cdc42-PAK pathway in cytoskeletal rearrangements. Acta Biochim Pol. 2009; 56:225-234.
79. Fukuyama T, Ogita H, Kawakatsu T, Fukuhara T, Yamada T, Sato T, Shimizu K, Nakamura T, Matsuda M and Takai Y. Involvement of the c-Src-Crk-C3G-Rap1 signaling in the nectin-induced activation of Cdc42 and formation of adherens junctions. J Biol Chem. 2005; 280:815-825.
80. Sharma A and Mayer BJ. Phosphorylation of p130Cas initiates Rac activation and membrane ruffling. BMC Cell Biol. 2008; 9:50.
81. Zhang XA, He B, Zhou B and Liu L. Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration. J Biol Chem. 2003; 278:27319-27328.
82. Klemke L, Leng, Molander, Brooks C, Vuori and Cheresh A. CAS/Crk coupling serves as a molecular switch for induction of cell migration. J Cell Biol. 1998; 140:961-972.
83. Nam J-S, Ino Y, Sakamoto M and Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin-catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res. 2002; 8:2430-2436.
84. Avizienyte E, Wyke AW, Jones RJ, McLean GW, Westhoff MA, Brunton VG and Frame MC. Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signalling. Nat Cell Biol. 2002; 4:632-8.
85. Roura S, Miravet S, Piedra J, Garcia de Herreros A and Dunach M. Regulation of E-cadherin/Catenin association by tyrosine phosphorylation. J Biol Chem. 1999; 274:36734-36740.
86. Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, Lochner D and Birchmeier W. E-cadherin-mediated cellcell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991; 113:173-185.
87. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998; 153:333-339.
88. Dorudi S, Sheffield JP, Poulsom R, Northover JM and Hart IR. E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol. 1993; 142:981-986.
89. Siitonen SM, Kononen JT, Helin HJ, Rantala IS, Holli KA and Isola JJ. Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol. 1996; 105:394-402.
90. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM and Schalken JA. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994; 54:3929-3933.
91. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES and Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008; 68:3645-3654.
92. Matsuyoshi N, Hamaguchi M, Taniguchi S, Nagafuchi A, Tsukita S and Takeichi M. Cadherin-mediated cell-cell adhesion is perturbed by v-src tyrosine phosphorylation in metastatic fibroblasts. J Cell Biol. 1992; 118:703-714.
93. Avizienyte E, Fincham VJ, Brunton VG and Frame MC. Src SH3/2 domain-mediated peripheral accumulation of Src and phospho-myosin is linked to deregulation of E-cadherin and the epithelial-mesenchymal transition. Mol Biol Cell. 2004; 15:2794-2803.
94. Maeda M, Shintani Y, Wheelock MJ and Johnson KR. Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II. J Biol Chem. 2006; 281:59-68.
95. Putzke AP, Ventura AP, Bailey AM, Akture C, OpokuAnsah J, Celiktas M, Hwang MS, Darling DS, Coleman IM, Nelson PS, Nguyen HM, et al. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am J Pathol. 2011; 179:400-410.
96. Hollier BG, Evans K and Mani SA. The epithelial-tomesenchymal transition and cancer stem cells: A coalition against cancer therapies. J Mammary Gland Biol Neoplasia. 2009; 14:29-43.
97. McLachlan RW, Kraemer A, Helwani FM, Kovacs EM and Yap AS. E-cadherin adhesion activates c-Src signaling at cell-cell contacts. Mol Biol Cell. 2007; 18:3214-3223.
98. Fujita Y, Krause G, Scheffner M, Zechner D, Leddy HE, Behrens J, Sommer T and Birchmeier W. Hakai, a c-Cbllike protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat Cell Biol. 2002; 4:222-231.
99. Palacios F, Tushir JS, Fujita Y and D'Souza-Schorey C. Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell-cell adhesion during epithelial to mesenchymal transitions. Mol Cell Biol. 2005; 25:389-402.
100. de Beco S, Gueudry C, Amblard F and Coscoy S. Endocytosis is required for E-cadherin redistribution at mature adherens junctions. Proc Natl Acad Sci U S A. 2009; 106:7010-7015.
101. Balzac F, Avolio M, Degani S, Kaverina I, Torti M, Silengo L, Small JV and Retta SF. E-cadherin endocytosis regulates the activity of Rap1: a traffic light GTPase at the crossroads between cadherin and integrin function. J Cell Sci. 2005; 118:4765-4783.
102. Meng W and Takeichi M. Adherens junction: molecular architecture and regulation. Cold Spring Harb Perspect Biol. 2009; 1:a002899.
103. Chen Y, Chen CH, Tung PY, Huang SH and Wang SM. An acidic extracellular pH disrupts adherens junctions in HepG2 cells by Src kinases-dependent modification of E-cadherin. J Cell Biochem. 2009; 108:851-859.
104. Reynolds AB and Roczniak-Ferguson A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene. 2004; 23:7947-7956.
105. Reynolds AB, Roesel DJ, Kanner SB and Parsons JT. Transformation-specific tyrosine phosphorylation of a novel cellular protein in chicken cells expressing oncogenic variants of the avian cellular src gene. Mol Cell Biol. 1989; 9:629-638.
106. Ozawa M and Ohkubo T. Tyrosine phosphorylation of p120(ctn) in v-Src transfected L cells depends on its association with E-cadherin and reduces adhesion activity. J Cell Sci. 2001; 114:503-512.
107. Reynolds AB and Carnahan RH. Regulation of cadherin stability and turnover by p120ctn: implications in disease and cancer. Semin Cell Dev Biol. 2004; 15:657-663.
108. Cho HJ, Baek KE and Yoo J. RhoGDI2 as a therapeutic target in cancer. Expert Opin Ther Targets. 2010; 14:67-75.
109. Ma L, Xu G, Sotnikova A, Szczepanowski M, Giefing M, Krause K, Krams M, Siebert R, Jin J and Klapper W. Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. Br J Haematol. 2007; 139:217-223.
110. Groysman M, Hornstein I, Alcover A and Katzav S. Vav1 and Ly-GDI two regulators of Rho GTPases, function cooperatively as signal transducers in T cell antigen receptor-induced pathways. J Biol Chem. 2002; 277:50121-50130.
111. Harding MA and Theodorescu D. RhoGDI signaling provides targets for cancer therapy. Eur J Cancer. 2010; 46:1252-1259.
112. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM and Frierson HF, Jr. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res. 2004; 10:3800-3806.
113. Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC and Knuutila S. Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet. 2001; 128:1-6.
114. Hu LD, Zou HF, Zhan SX and Cao KM. Biphasic expression of RhoGDI2 in the progression of breast cancer and its negative relation with lymph node metastasis. Oncol Rep. 2007; 17:1383-1389.
115. DerMardirossian C, Rocklin G, Seo JY and Bokoch GM. Phosphorylation of RhoGDI by Src regulates Rho GTPase binding and cytosol-membrane cycling. Mol Biol Cell. 2006; 17:4760-4768.
116. Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA and Theodorescu D. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proc Natl Acad Sci U S A. 2009; 106:5807-5812.
117. Benitah SA, Valeron PF, van Aelst L, Marshall CJ and Lacal JC. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta. 2004; 1705:121-132.
118. Ridley AJ. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. Trends Cell Biol. 2006; 16:522-529.
119. Nauert JB, Klauck TM, Langeberg LK and Scott JD. Gravin, an autoantigen recognized by serum from myasthenia gravis patients, is a kinase scaffold protein. Curr Biol. 1997; 7:52-62.
120. Frankfort BJ and Gelman IH. Identification of novel cellular genes transcriptionally suppressed by v-src. Biochem Biophys Res Commun. 1995; 206:916-926.
121. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, et al. Molecular portraits of human breast tumours. Nature. 2000; 406:747-752.
122. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA and Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001; 412:822-826.
123. Xia W, Unger P, Miller L, Nelson J and Gelman IH. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res. 2001; 61:5644-5651.
124. Gelman IH. Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12. Cancer Metastasis Rev. 2012; 31:493-500.
125. Akakura S and Gelman IH. Pivotal role of AKAP12 in the regulation of cellular adhesion dynamics: control of cytoskeletal architecture, cell migration, and mitogenic signaling. J Signal Transduct. 2012; 2012:529179.
126. Welsh JB, Zarrinkar PP, Sapinoso LM, Kern SG, Behling CA, Monk BJ, Lockhart DJ, Burger RA and Hampton GM. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2001; 98:1176-1181.
127. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, Altman RB, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A. 2001; 98:13784-13789.
128. Choi MC, Jong HS, Kim TY, Song SH, Lee DS, Lee JW, Kim TY, Kim NK and Bang YJ. AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene. 2004; 23:7095-7103.
129. Gelman IH. The role of SSeCKS/gravin/AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. Front Biosci. 2002; 7:d1782-1797.
130. Streb JW, Kitchen CM, Gelman IH and Miano JM. Multiple promoters direct expression of three AKAP12 isoforms with distinct subcellular and tissue distribution profiles. J Biol Chem. 2004; 279:56014-56023.
131. Bu Y and Gelman IH. v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex. J Biol Chem. 2007; 282:26725-26739.
132. Bu Y, Gao L and Gelman IH. Role for transcription factor TFII-I in the suppression of SSeCKS/Gravin/Akap12 transcription by Src. Int J Cancer. 2011; 128:1836-1842.
133. Su B, Gao L, Meng F, Guo LW, Rothschild J and Gelman IH. Adhesion-mediated cytoskeletal remodeling is controlled by the direct scaffolding of Src from FAK complexes to lipid rafts by SSeCKS/AKAP12. Oncogene. 2013; 32:2016-2026.
134. Liu Y, Gao L and Gelman IH. SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis. BMC Cancer. 2006; 6:105.
135. Gelman IH and Gao L. SSeCKS/Gravin/AKAP12 metastasis suppressor inhibits podosome formation via RhoA-and Cdc42-dependent pathways. Mol Cancer Res. 2006; 4:151-158.
136. Kokame K, Kato H and Miyata T. Homocysteinerespondent genes in vascular endothelial cells identified by differential display analysis. GRP78/BiP and novel genes. J Biol Chem. 1996; 271:29659-29665.
137. Zhou D, Salnikow K and Costa M. Cap43, a novel gene specifically induced by Ni2+ compounds. Cancer Res. 1998; 58:2182-2189.
138. Park H, Adams MA, Lachat P, Bosman F, Pang SC and Graham CH. Hypoxia induces the expression of a 43-kDa protein (PROXY-1) in normal and malignant cells. Biochem Biophys Res Commun. 2000; 276:321-328.
139. Thierry-Mieg D and Thierry-Mieg J. AceView: a comprehensive cDNA-supported gene and transcripts annotation. Genome Biol. 2006; 7 Suppl 1:S12 11-14.
140. van Belzen N, Dinjens WN, Eussen BH and Bosman FT. Expression of differentiation-related genes in colorectal cancer: possible implications for prognosis. Histol Histopathol. 1998; 13:1233-1242.
141. Ellen TP, Ke Q, Zhang P and Costa M. NDRG1, a growth and cancer related gene: regulation of gene expression and function in normal and disease states. Carcinogenesis. 2007; 29:2-8.
142. Mao Z, Sun J, Feng B, Ma J, Zang L, Dong F, Zhang D and Zheng M. The metastasis suppressor, N-myc downregulated gene 1 (NDRG1), is a prognostic biomarker for human colorectal cancer. PLoS One. 2013; 8:e68206.
143. Liu R, Li J, Teng Z, Zhang Z and Y Xu. Overexpressed microRNA-182 promotes proliferation and invasion in prostate cancer PC-3 cells by down-regulating N-myc downstream regulated gene 1 (NDRG1). PLoS One. 2013; 16:e68982.
144. Zhao G, Chen J, Deng Y, Gao F, Zhu J, Feng Z, Lv X and Zhao Z. Identification of NDRG1-regulated genes associated with invasive potential in cervical and ovarian cancer cells. Biochem Biophys Res Commun. 2011; 408:154-159.
145. Cheng J, Xie HY, Xu X, Wu J, Wei X, Su R, Zhang W, Lv Z, Zheng S and Zhou L. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 2011; 310:35-45.
146. Ma W, Na M, Tang C, Wang H and Lin Z. Overexpression of N-myc downstream-regulated gene 1 inhibits human glioma proliferation and invasion via phosphoinositide 3-kinase/AKT pathways. Mol Med Rep. 2015; 12:1050-1058.
147. Hosoi F, Izumi H, Kawahara A, Murakami Y, Kinoshita H, Kage M, Nishio K, Kohno K, Kuwano M and Ono M. N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression. Cancer Res. 2009; 69:4983-4991.
148. Sun B, Chu D, Li W, Chu X, Li Y, Wei D and Li H. Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. J Neurooncol. 2009; 94:213-219.
149. Kovacevic Z, Fu D and Richardson DR. The ironregulated metastasis suppressor, Ndrg-1: Identification of novel molecular targets. Biochim Biophys Acta. 2008; 1783:1981-1992.
150. Zhang AH, Rao JN, Zou T, Liu L, Marasa BS, Xiao L, Chen J, Turner DJ and Wang JY. p53-dependent NDRG1 expression induces inhibition of intestinal epithelial cell proliferation but not apoptosis after polyamine depletion. Am J Physiol Cell Physiol. 2007; 293:C379-389.
151. Lv XH, Chen JW, Zhao G, Feng ZZ, Yang DH, Sun WW, Fan JS and Zhu GH. N-myc downstream-regulated gene 1/Cap43 may function as tumor suppressor in endometrial cancer. J Cancer Res Clin Oncol. 2012; 138:1703-1715.
152. Dominguez R and Holmes KC. Actin structure and function. Annual review of biophysics. 2011; 40:169-186.
153. Watanabe N, Kato T, Fujita A, Ishizaki T and Narumiya S. Cooperation between mDia1 and ROCK in Rho-induced actin reorganization. Nat Cell Biol. 1999; 1:136-143.
154. Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM and Pardee AB. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res. 2000; 60:749-755.
155. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z and Gallick GE. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008; 68:3323-3333.
156. Liu W, Yue F, Zheng M, Merlot AM, Bae DH, Huang ML, Lane DJR, Jansson PJ, Lui GYL, Richardson V, Sahni S, et al. The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget. 2015; 6:8851-74.
157. Tikhmyanova N, Little JL and Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci. 2010; 67:1025-1048.
158. Le NTV and Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood. 2004; 104:2967-2975.
159. Lane DJ, Saletta F, Suryo Rahmanto Y, Kovacevic Z and Richardson DR. N-myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion. PLoS One. 2013; 8:e57273.
160. El Touny LH and Banerjee PP. Genistein induces the metastasis suppressor kangai-1 which mediates its antiinvasive effects in TRAMP cancer cells. Biochem Biophys Res Commun. 2007; 361:169-175.
161. Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y, Ishibashi Y, et al. Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 2001; 411:613-617.
162. Mashimo T, Watabe M, Hirota S, Hosobe S, Miura K, Tegtmeyer PJ, Rinker-Shaeffer CW and Watabe K. The expression of the KAI1 gene, a tumor metastasis suppressor, is directly activated by p53. Proc Natl Acad Sci U S A. 1998; 95:11307-11311.
163. Mashimo T, Bandyopadhyay S, Goodarzi G, Watabe M, Pai SK, Gross SC and Watabe K. Activation of the tumor metastasis suppressor gene, KAI1, by etoposide is mediated by p53 and c-Jun genes. Biochem Biophys Res Commun. 2000; 274:370-376.
164. Titus B, Frierson HF, Jr., Conaway M, Ching K, Guise T, Chirgwin J, Hampton G and Theodorescu D. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res. 2005; 65:7320-7327.
165. Lalich M, McNeel DG, Wilding G and Liu G. Endothelin receptor antagonists in cancer therapy. Cancer Invest. 2007; 25:785-794.
166. Merlot AM, Kalinowski DS and Richardson DR. Novel chelators for cancer treatment: where are we now? Antioxid Redox Signal. 2013; 18:973-1006.
167. Yuan J, Lovejoy DB and Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 2004; 104:1450-1458.
168. Whitnall M, Howard J, Ponka P and Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A. 2006; 103:14901-14906.
169. Chua ACG, Graham RM, Trinder D and Olynyk JK. The regulation of cellular iron metabolism. Crit Rev Clin Lab Sci. 2007; 44:413-459.
170. Kalinowski DS and Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005; 57:547-583.
171. Kwok JC and Richardson DR. The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol. 2002; 42:65-78.
172. Richardson DR. Iron chelators as therapeutic agents for the treatment of cancer. Crit Rev Oncol Hematol. 2002; 42:267-281.
173. Walker RA and Day SJ. Transferrin receptor expression in non-malignant and malignant human breast tissue. J Pathol. 1986; 148:217-224.
174. Prutki M, Poljak-Blazi M, Jakopovic M, Tomas D, Stipancic I and Zarkovic N. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer letters. 2006; 238:188-196.
175. Lovejoy DB, Jansson PJ, Brunk UT, Wong J, Ponka P and Richardson DR. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redoxactive copper complex that accumulates in lysosomes. Cancer Res. 2011; 71:5871-5880.
176. Jansson PJ, Hawkins CL, Lovejoy DB and Richardson DR. The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study. J Inorg Biochem. 2010; 104:1224-1228.
177. Jansson PJ, Sharpe PC, Bernhardt PV and Richardson DR. Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem. 2010; 53:5759-5769.
178. Lui GYL, Obeidy P, Ford SJ, Tselepis C, Sharp DM, Jansson PJ, Kalinowski DS, Kovacevic Z, Lovejoy DB and Richardson DR. The iron chelator, Deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action. Mol Pharmacol. 2012; 83:179-190.
179. Gao J and Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression. Blood. 2001; 98:842-850.
180. Kovacevic Z, Chikhani S, Lovejoy DB and Richardson DR. Novel thiosemicarbazone iron chelators induce upregulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol. 2011; 80:598-609.
181. Bandyopadhyay S, Pai SK, Gross SC, Hirota S, Hosobe S, Miura K, Saito K, Commes T, Hayashi S, Watabe M and Watabe K. The Drg-1 gene suppresses tumor metastasis in prostate cancer. Cancer Res. 2003; 63:1731-1736.
182. Bandyopadhyay S, Pai SK, Hirota S, Hosobe S, Takano Y, Saito K, Piquemal D, Commes T, Watabe M, Gross SC, Wang Y, et al. Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression. Oncogene. 2004; 23:5675-5681.
183. Lovejoy DB, Sharp DM, Seebacher N, Obeidy P, Prichard T, Stefani C, Basha MT, Sharpe PC, Jansson PJ, Kalinowski DS, Bernhardt PV and Richardson DR. Novel second-generation di-2-pyridylketone thiosemicarbazones show synergism with standard chemotherapeutics and demonstrate potent activity against lung cancer xenografts after oral and intravenous administration in vivo. J Med Chem. 2012; 55:7230-7244.
184. Lui GY, Kovacevic Z, Richardson V, Merlot AM, Kalinowski DS and Richardson DR. Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget. 2015; 6:18748-18779.